Market Spotlight: Renal Disease
Market Spotlight: Renal Disease
$1,318.00
This Market Spotlight report covers the Renal Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Renal Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2018, there were approximately 738.0 million prevalent cases of chronic kidney disease (all stages) in adults aged 20 years and over worldwide. This figure is forecasted to increase to 819.5 million by 2027.
- Datamonitor Healthcare estimates that in 2018, there were 166.6 million cases (22.6%) in stage 1, 185.7 million cases (25.2%) in stage 2, 361.8 million cases (49.0%) in stage 3, 19.0 million cases (2.6%) in stage 4, and 4.8 million cases (0.4%) in stage 5.
- The approved drugs in the renal disease space focus on a wide variety of targets. The majority of these therapies are administered via the oral route, with the remainder being intravenous, intramuscular, and subcutaneous formulations.
- The largest proportion of industry-sponsored drugs in active clinical development for renal disease are in Phase II. Therapies in the pipeline for renal disease focus on a wide variety of targets. The majority of these therapies are administered orally, with the remainder being intravenous, subcutaneous, hemoperfusion, intramuscular, and topical formulations.
- High-impact upcoming events for drugs in the renal disease space comprise topline Phase I/II trial results for CLBS201; topline Phase II trial results for suramin, ANG-3777, and bardoxolone methyl; topline Phase IIb trial results for AZD5718; and topline Phase III trial results for Sibnayal, veverimer, recAP, and Jardiance.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for renal disease have been in the early and mid-phases of development, with 56% of trials in Phase I–II, and 44% in Phase III–IV.
- The US has a substantial lead in the number of renal disease clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the renal disease space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for ren
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Patient segmentation
9 Symptoms
9 Risk factors
9 Diagnosis
11 TREATMENT
11 Treatment of acute kidney injury
11 Treatment of chronic kidney disease
14 EPIDEMIOLOGY
19 MARKETED DRUGS
22 PIPELINE DRUGS
29 RECENT EVENTS AND ANALYST OPINION
29 Veverimer for Renal Disease (February 25, 2021)
30 Veverimer for Renal Disease (December 8, 2020)
32 Veverimer for Renal Disease (October 20, 2020)
33 Farxiga for Renal Disease (August 30, 2020)
36 Veverimer for Renal Disease (August 21, 2020)
38 Farxiga for Renal Disease (July 28, 2020)
39 Veverimer for Renal Disease (July 14, 2020)
41 Farxiga for Renal Disease (March 30, 2020)
43 KEY UPCOMING EVENTS
44 KEY REGULATORY EVENTS
44 Advicenne Hastens EU Approval For Sibnayal By Withdrawing Orphan Designation
44 AstraZeneca’s Farxiga Moves Into CKD – Regardless Of Diabetes Status
44 EU Accelerated Assessment Tracker
45 Reata Seeks Priority Review For Bardoxolone
45 New To The Review Queue
45 Farxiga BTD Rests On Renal Outcomes Trial DAPA-CKD
46 LICENSING AND ASSET ACQUISITION DEALS
46 Arch Gets Rights To Cilastatin From Telara
46 Chinook, Evotec Partner On CKD Precision Medicine
46 VTv Licenses Renal Disease Candidate To Anteris
46 Spectrum Licenses CKD Therapy To Unicycive
48 REVENUE OPPORTUNITY
49 CLINICAL TRIAL LANDSCAPE
50 Sponsors by status
51 Sponsors by phase
52 Recent events
54 BIBLIOGRAPHY
55 APPENDIX
LIST OF FIGURES
17 Figure 1: Trends in prevalent cases of chronic kidney disease, 2018–27
22 Figure 2: Overview of pipeline drugs for renal disease in the US
22 Figure 3: Pipeline drugs for renal disease, by company
23 Figure 4: Pipeline drugs for renal disease, by drug type
23 Figure 5: Pipeline drugs for renal disease, by classification
36 Figure 6: Farxiga for Renal Disease (August 30, 2020): Phase III – DAPA-CKD
39 Figure 7: Farxiga for Renal Disease (July 28, 2020): Phase III – DAPA-CKD
43 Figure 8: Key upcoming events in renal disease
49 Figure 9: Clinical trials in renal disease
49 Figure 10: Top 10 drugs for clinical trials in renal disease
50 Figure 11: Top 10 companies for clinical trials in renal disease
50 Figure 12: Trial locations in renal disease
51 Figure 13: Renal disease trials status
52 Figure 14: Renal disease trials sponsors, by phase
LIST OF TABLES
15 Table 1: Prevalent cases of chronic kidney disease, 2018–27
18 Table 2: Prevalent cases of chronic kidney disease, by stage, 2018
20 Table 3: Marketed drugs for renal disease
24 Table 4: Pipeline drugs for renal disease in the US
29 Table 5: Veverimer for Renal Disease (February 25, 2021)
31 Table 6: Veverimer for Renal Disease (December 8, 2020)
32 Table 7: Veverimer for Renal Disease (October 20, 2020)
33 Table 8: Farxiga for Renal Disease (August 30, 2020)
37 Table 9: Veverimer for Renal Disease (August 21, 2020)
38 Table 10: Farxiga for Renal Disease (July 28, 2020)
40 Table 11: Veverimer for Renal Disease (July 14, 2020)
41 Table 12: Farxiga for Renal Disease (March 30, 2020)
48 Table 13: Historical global sales, by drug ($m), 2016–20
48 Table 14: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Disease Analysis: Hepatitis C 
Sign up to the